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Abstract: Obesity is a global epidemic associated with significant morbidity and mortality in 
adults and ill health in children. A proven successful approach in weight management has been the 
disruption of nutrient digestion, with orlistat having been used to treat obesity for the last 10 years. 
Although orlistat-induced weight loss remains modest, it produces meaningful reductions in risk 
factors for obesity-related conditions such as diabetes and cardiovascular disease. Moreover, 
this lipase inhibitor is free of the serious side effects that have dogged appetite-suppressing 
drugs. This success had driven investigation into new generation nutraceuticals, supplements 
and pharmaceutical agents that inhibit the breakdown of complex carbohydrates and fats within 
the gut. This review focuses on agents purported to inhibit intestinal enzymes responsible for 
macronutrient digestion. Except for some synthetic products, the majority of agents reviewed 
are either botanical extracts or bacterial products. Currently, carbohydrate digestion inhibitors 
are under development to improve glycemic control and these may also induce some weight loss. 
However, colonic fermentation induced side effects, such as excess gas production, remain an 
issue for these compounds. The α-glucosidase inhibitor acarbose, and the α-amylase inhibitor 
phaseolamine, have been used in humans with some promising results relating to weight loss. 
Nonetheless, few of these agents have made it into clinical studies and without any clinical proof 
of concept or proven efficacy it is unlikely any will enter the market soon.
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Prevalence and impact of obesity
A positive energy balance resulting from a chronic disparity between the intake of 
energy and its expenditure leads to weight gain and eventually obesity. Currently, 
the global tendency to gain weight poses a major menace to world health. Adiposity 
(overweight and obesity) constitutes a key risk factor for a variety of adulthood chronic 
disorders such as dyslipidemia, high blood pressure, type II diabetes, cardiovascular 
disease, osteoarthritis and some forms of cancer.1 In the European Region, 2% to 8% 
of health costs could be attributable to obesity.2 Obesity can no longer be considered 
only a problem of developed, ‘Westernized’, high income countries. On every continent 
developing countries are experiencing similar increases in the prevalence of overweight 
and obesity within their population, particularly in urban settings.
Currently, a body mass index (BMI) of 30 kg/m2 or greater defines adult obesity, and 
between 25 and 29.9 kg/m2 is classified as overweight. However, lower cut off points 
should be used in certain populations at greater risk of obesity related diseases. In 2005, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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the World Health Organization (WHO) reported that 1.6 billion 
adults could be categorized as overweight whilst at least 400 
million adults were considered obese.3 The WHO predicted that 
over the next ten years global rates of overweight and obesity 
would double, and by 2015 roughly 2.3 billion adults would be 
overweight and over 700 million obese. Europe has followed the 
global trend – since 1980 the prevalence of obesity has tripled, 
with levels continuing to rise at an alarming rate.
For intervention, the most common and widely advocated 
approaches remain changes in lifestyle, specifically dieting and 
exercise. Achieving significant weight loss is a difficult task and 
although some individuals manage to lose weight in the short 
term, for most people maintaining a lower body weight in the 
long term proves remarkably difficult.4,5 Drug therapy offers a 
reasonable option to overcome obesity when given as an adjunct 
to life style interventions such as dietary counseling, behavioral 
modifications and   structured exercise.6,7 Modest weight reduc-
tion (5% to 10% of total body weight) in patients with obesity-
associated medical complications produces beneficial health 
outcomes. A reduction of 5 to 10 kg of body weight in moderately 
obese patients reduces blood pressure and cholesterol levels, 
and improves glycemia along with a reduced risk of undesirable 
clinical outcomes including myocardial infarction, stroke and 
  cardiovascular-related death8 and increases longevity.9
The phenomenon of weight gain suggests that the 
homeostatic mechanisms regulating energy homeostasis 
are insufficient to cope with our current obesity promoting 
environment. However, boosting inhibitory homeostatic 
feedback could re-establish effective homeostatic control of 
energy balance and even induce weight loss. Consequently, 
the mechanisms underpinning the regulation of appetite and 
energy regulation have received particular attention, notably 
for the development of anti-obesity drugs.10,11 These include 
drugs that reduce appetite and/or enhance satiety or drugs 
that stimulate energy expenditure thereby restoring energy 
balance. Although providing a rich source of drug targets 
for weight control, this approach ignores the possibility that 
over-consumption associated with obesity results from the 
stimulatory effect of the food environment rather than any 
particular biological deficit (such as in post ingestive satiety 
from the gut or increased adiposity signals from body fat 
stores). The withdrawal of appetite-suppressing drugs that 
act on the central nervous system such as fenfluramine, 
d-fenfluramine, rimonabant and sibutramine (withdrawn in 
Europe but still available in the US), suggests that targeting 
energy regulation systems for weight control is not   without 
  problems. Even peripheral appetite targets such as gut 
  peptides implicated in the processes of satiation and satiety 
such as glucagon-like peptide-1 (GLP)-1 and peptide YY 
(PYY) are difficult to administer and may induce nausea.
Nonetheless, drugs acting in the periphery provide a 
viable alternative for weight management and other pharma-
cological approaches to the treatment of obesity have proved 
successful, specifically drugs that affect the absorption or 
partitioning of nutrients.12 A lipase inhibitor is currently the 
only prescription medicine available in Europe for obesity 
treatment. This review will focus on drugs that have, as a 
potential mechanism, the disruption of fat and carbohydrate 
absorption. Tables 1 and 2 summarize the doses and effects 
found in vitro and in vivo studies.
Dietary fat digestion and absorption
Lipids are fundamental components of all living organisms, 
and they are calorically dense thus representing an important 
constituent of human nutrition (approximately 40% of daily 
energy intake). Dietary fats are absorbed in the intestine 
and they function as an energy supply, thermal regulators, 
membrane constituents, energy storage and some play an 
important role in body function as essential fatty acids and 
fat-soluble vitamins.13 The human intestine is able to com-
pletely absorb approximately 95% of ingested fat.14 Given 
the efficient absorption of dietary fat it is not surprising that 
long term intake of a high fat diet is readily converted to 
adipose tissue particularly in those with low levels of physical 
activity.15 In such a scenario it is logical to assume that the 
modification of fat absorption could be a potential target to 
treat obesity and prevent further weight gain.
The main fat constituents (90%) of a typical Western 
diet are triacylglycerols or triglycerides (TG). TG consist 
of a single molecule of glycerol, attached by ester bonds 
to three fatty acids. TG cannot be absorbed; therefore, 
intestinal enzymes must hydrolyze the ester bonds on the 
glycerol backbone in order for the molecule to be absorbed. 
The products of this hydrolysis are mainly free fatty acids 
(FFA) and 2- monoglycerides (2-MG) which can be absorbed 
by the duodenum. In vivo TG hydrolysis is catalyzed by 
several digestive lipases. There are several human lipases 
which include the pre-duodenal (lingual and human gastric 
lipase (HGL)) and the extra-duodenal (pancreatic, hepatic, 
lipoprotein and endothelial) lipases.16
Lingual lipase is secreted by a serous gland at the back of 
the tongue and initiates fat digestion.17 HGL is secreted by the 
chief cells of the fundic mucosa of the stomach, this enzyme 
is active at a broad pH range (3 to 6) and is stable even at the 
low pH present in the stomach.18 The acinar cells of the pan-
creas synthesize and secrete several lipolytic enzymes such as Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Table 1 effective in vitro doses and target enzymes of inhibitors
Product Dose Effect Ref
Cetilistat 54.8 nmol/L 
5.95 nmol/L 
inhibits rat pancreatic lipase 
inhibits HPL
46
Platycodin D1 saponin 0.18–0.03 mM  inhibits pancreatic lipase 82
Sabiosaponin prosapogenin 1b  0.12 mg/mL inhibits pancreatic lipase 87
Acanthopanax sessiliflorus 
sessiloside and chiisanoside 
0.36 and 0.75 mg/mL, respectively inhibit pancreatic lipase 53
Acanthopanax senticosus 
triterpenoid saponins
0.22–0.29 mM inhibit pancreatic lipase 
inhibits glucose 6-phosphatase and 
lipogenic enzymes in liver
52,61
Panax japonicum 
chikusetsusaponin
125–500 μg/mL inhibits pancreatic lipase 76
Dioscorea nipponica extract  5–10 mg/mL inhibits pancreatic lipase 72
Kochia scoparia alcohol extract and saponins 0.25 mg/mL inhibit pancreatic lipase 213
Aesculus turbinata escins  20–100 μM inhibit pancreatic lipase 70
Sapindus rarak extract and saponins extract: iC50 = 614 μg/mL 
Rarasaponins i iC50 = 131 μM 
and ii 172 μM
inhibit pancreatic lipase 86
Oolong tea saponins 
(theasaponins e1 and e2) 
Km and vmax values of  
1.42 mg/mL and 476.2 nkat/L 
respectively. The Ki value of 
theasaponin is 0.25 mg/mL
inhibit pancreatic lipase 73,74
Chinese tea saponins chakasaponins i, ii, and iii iC50 of 0.091 mg/mL 
iC50 values of 0.17–0.53 mM
inhibit pancreatic lipase 71
Oolong tea catechins  
epigallocatechin 3-O-gallate(-) 
epigallocatechin-3,5-digallate
05–2 g/L 
0.34 μM 
0.09 μM
inhibit pancreatic lipase 
inhibit pancreatic lipase 
inhibit pancreatic lipase
73,203
Green tea catechins 5–30 μM inhibit adipocytes differentiation 
inhibit gastric and pancreatic lipase 
inhibit α-amylase and α-glucosidase
187–189,191,192
Cyclocarya paliurus  5 μg/mL 
9.1 μg/mL
inhibits α-glucosidase 
inhibits pancreatic lipase
180,181
Salacia reticulata polyphenol extracts 
salacinol and kotalanol 
iC50 of 264 mg/L  inhibit pancreatic lipase 
inhibit α-glucosidase
210 
Apple polyphenol procyanidin fractions  iC50 of 5.6 μg/mL 
iC50 of 1.4 μg/mL
inhibit pancreatic lipase 97
Grape seed extract 1 mg/mL 80% inhibition  inhibits pancreatic lipase  101
Nelumbo nucifera extract  iC50 of 0.46 mg/mL 
iC50 of 0.82 mg/mL
inhibits lipase 
inhibits α-amylase
199
Cassia mimosoides CT-iia extract 0.1–0.71 mg/μmL  50% inhibition porcine lipase  98
Peanut shell extract  10 mg/mL  92% inhibition of human lipase 207
Carnosic acid and carnasol  iC50 of 36 μM 
iC50 of 13 and μM 
inhibit pancreatic lipase 104
Crocetin iC50 of 2.1 mg/mL  inhibits pancreatic lipase  109
Lipstatin  iC50 of 0.14 μM  inhibits pancreatic lipase 110
Panclicins A, B, C, D e 2.9, 2.6, 0.62, 0.66, and 0.89 μM inhibit pancreatic lipase 131
vibralactone iC50 of 0.4 μg/mL inhibits pancreatic lipase 133
aethanol extract.
Abbreviations: HPL, triacylglycerol acyl hydrolase.
colipase-dependent lipase, classical   pancreatic lipase or tria-
cylglycerol acyl hydrolase (HPL), pancreatic lipase related-
protein 1 and 2 (HPLRP1, HPLRP2), carboxyl ester hydrolase 
(also known as bile salt stimulated lipase, carboxyl ester 
lipase, cholesterol esterase, cholesterol ester lipase, human 
milk lipase, monoglyceride lipase and pancreatic non-specific 
lipase) and phospholipase A2.17,19 Cholesterol esters, lipidic 
vitamin esters, monoglycerides, diglycerides, TG, and phos-
pholipids are hydrolyzed mainly by carboxyl ester hydrolase. 
The pancreas also secretes colipase, a factor that is neces-
sary to optimize pancreatic lipase activity. Colipase binds 
to bile acid micelles and   phospholipid-covered   emulsions. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Table 2 enzyme inhibitors: doses and in vivo effects
Product Dose Effect Ref
Cetilistat 3–100 mg/kg; DiO rats 
80–720 mg/day; humans
↓ TG plasma levels 
↑ Fat excretion 
Suppression of body weight gain 
↓ white adipose tissue 
↓ Body weight
46,48,49
Acanthopanax sessiliflorus  100–300 mg/kg; 
vO, mice 
↓ TG plasma levels 
↑ TG in intestinal lumen
66
Acanthopanax senticosus extracts 12 mg/kg; DiO mice ↓ TG in liver and serum 
↓ LDL in serum 
↑ HDL
63
Panax japonicum total chikusetsusaponins 1%–3% of diet; DiO mice Suppression of body weight gain 
↓ Parametrial adipose tissue weight 
76
Dioscorea nipponica dioscin and diosgenin 100 mg/kg; vO, mice 
5% of high fat diet, rats
↓ TG in plasma 
Suppression of body weight gain 
↓ vLDL and LDL in plasma
72
Aesculus turbinata 0.1%–0.5% of diet; DiO mice  Suppression of body weight gain 
↓ Parametrial adipose tissue weight 
↓ TG in plasma
68
Cyclocarya paliurus extract  250 mg/kg; vO, mice ↓ increase in blood glucose after 
sucrose administration 
↓ TG in plasma
180,181
Salacia reticulata extract  125 mg/kg; vO, Zucker and HFD rats  Suppression of body weight gain 210
Apple polyphenol and procyanidin fractions  200 mg/kg; vO, mice 
600 mg; vO, humans
↓ TG in plasma after corn oil loading 
inhibition of TG increase after TG load
97
Nelumbo nucifera 5% of diet; mice ↓ Body weight 
↓ TG in plasma 
↓ Parametrial adipose tissue weight
199
Cassia mimosoides CT-iia extract 1%–3.5% of diet; DiO rats Suppression of body weight gain 
↓ Parametrial adipose tissue weight
98
Peanut shell extract  1% of diet; DiO rats  Suppression of body weight gain 207
Carnosic acid 20 mg/kg; vO, DiO mice Suppression of body weight gain 104
Crocetin and crocin  50 mg/kg; vO, mice  Suppression of body weight gain 
↓ epididymal fat pad
109
Lipstatin 375–750 mg/day; humans ↑ Fat excretion
118
Green tea catechins 5–80 mg; vO, rats inhibition of α-amylase and 
α-glucosidase
191
Note: aethanol extract. 
Abbreviations: DiO, diet-induced obesity; HFD, high-fat diet; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglycerides; vLDL, 
very-low-density lipoprotein cholesterol; vO, volume overload.
Once bound to these   surfaces, colipase facilitates the interac-
tion between pancreatic lipase and the surface of emulsified 
lipid droplets.20 Although HPLRP1 and -2 share a high degree 
of structural homology and sequence with HPL,21 their role 
in lipid digestion has not been fully clarified. It is known 
that under physiological conditions HPLRP1 does not exert 
lipolytic activity.21,22 HPLRP2 hydrolyzes galactolipids,23,24 
phospholipids and TG at a low rate,23 and retinyl ester.25 
HPLRP2 does not need colipase to be active.23
The hydrolysis of dietary TG starts in the stomach by the 
catalytic action of HGL. The secretion of HGL is induced 
by mechanical stimulation of the stomach, ingestion of food 
or sympathetic activation.17 HGL hydrolyzes 5% to 40% of 
ingested TG,26 mainly generating FFA, diglycerides, and a 
few 2-MG molecules.27 Gastric lipolysis is crucial for the 
continuation of the digestion process in the duodenum by 
HPL. Gastric lipolysis ensures: (i) lipid emulsification which 
creates the lipid–water interface needed for effective lipolysis 
in the duodenum,27–29 (ii) the generation of long-chain FFA 
which, once in the duodenum, will stimulate the release of 
cholecystokinin (CCK) and HPL secretion, slowing down 
gastric emptying,18 and (iii) the generation of diglycerides, 
which are hydrolyzed more effectively than TG.30 Therefore, 
the impact of HPL inhibition on lipid absorption is limited by 
the activity of HGL.31 The hydrolysis of TG persists in the 
duodenum by means of the combined actions of HGL (HGL Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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is responsible for further lipolysis contributing 7.5% to total 
lipolysis in the duodenum), HPL and bile salts. HPL is the 
principal pancreatic lipolytic enzyme; it hydrolyzes 40% to 
70% of TG26,28,29 yielding 2-MG and long-chain saturated and 
polyunsaturated FFA as the lipolytic products.16,31,32 For full 
activity under physiological conditions, HPL requires the 
presence of another pancreatic exocrine protein: colipase. 
Colipase is secreted as a precursor molecule, in the pres-
ence of bile salts, pro-colipase binds, without inducing any 
conformational change, to the C-terminal domain of the 
HPL molecule.33 In order to be absorbed, bile-derived mixed 
micelles convert FFA and 2-MG into soluble aggregates. 
These micelles transport these lipolytic products from the 
intestinal lumen to the intestinal walls.13,14 Once in contact 
with the enterocyte, the molecules are transported across 
the cell membrane. The enterocyte re-esterifies 2-MG and 
FFA into TG, assembles them into chylomicrons and then 
secretes these into the lymphatic system in order make them 
bioavailable.19,30,34 Lipolysis rates and consequently FFA 
supply to the body can be affected by several factors such 
as lipase levels and activity, physicochemical properties of 
dietary lipids, and the presence of inhibitors or enhancers.
Carbohydrate digestion  
and absorption
In humans, between 40% and 80% of total caloric intake 
is accounted for by carbohydrates in their various forms, 
making them the most important energy source. According 
to their chemical structure carbohydrates can be classi-
fied into absorbable (undigested), digestible, fermentable 
and non-fermentable forms.35 Absorbable carbohydrates 
(monosaccharides, comprising a single unit such as glu-
cose, galactose, fructose, xylose and ribose) by definition 
do not need to be digested in order to be transported into 
the body. However, once a carbohydrate comprises two or 
more units, it has to be enzymatically digested for it to be 
absorbed. In the human diet, the main digestible carbohy-
drates comprise disaccharides such as sucrose (sugar) and 
lactose, and larger polysaccharides such as starch which 
constitute a main source of calories in most Western diets. 
In contrast, fermentable carbohydrates cannot be digested 
as enzymes cannot readily break the inter saccharide bonds. 
However, once in the colon these carbohydrates are read-
ily metabolized by colonic bacteria through the process of 
fermentation. Similarly, if digestible carbohydrates such as 
sucrose and lactose are maldigested or malabsorbed, they 
will also be fermented in the large intestine. The main end 
products of carbohydrate fermentation are short-chain fatty 
acids (acetate, propionate, and butyrate) and gases (carbon 
dioxide, hydrogen, and methane).36 They can be absorbed 
in the large intestine (providing energy), used as a bacterial 
substrate, released as flatus, or excreted as biomass in the 
feces. Some carbohydrates (such as components of plant cell 
walls) are neither digested/absorbed nor fermented. They pass 
through the gastrointestinal (GI) tract mostly unchanged and 
are eliminated in the feces.
The digestion of carbohydrates begins in the mouth by 
the action of salivary α-amylase, which hydrolyzes the α-1,4 
bonds in starch, the products of this process are maltose, 
maltriose, and small dextrins. The starch digestion process 
continues in the small intestine by the action of pancreatic 
α-amylase. The digestion process is completed by enzymes 
in the brush border of the small intestine (maltase, sucrase, 
and lactase, also known as disaccharidases or α-glucosidases) 
which yields the absorbable monosaccharides glucose, fruc-
tose, and galactose. A small proportion of monosaccharides 
can be absorbed passively; however, a carrier protein is 
required to absorb the amount ingested in a normal diet.37
Drugs that interfere with lipid 
absorption
Although lipid metabolism is balanced to maintain homeo-
stasis, high-fat diets tend to induce overconsumption and 
as a consequence, weight gain. This is mainly due to their 
high energy content and their low potential for inducing 
satiety.38,39 It has been proposed that in the vast majority 
of cases, overweight and obesity are the consequences of 
exaggerated consumption of fat rather than carbohydrates.40 
This does not mean that obesity is not also associated with 
the consumption of refined sweet carbohydrates, but rather 
that the intake of this form of carbohydrate is invariably 
coupled with the intake of dietary fat (in sweet snack foods, 
sodas and desserts) along with the consumption of high fat 
savory food items (these often also contain considerable 
amounts of refined carbohydrates). Given the central role 
of dietary fat in weight gain, a rational strategy would be to 
reduce the proportion of calories derived from fat in the 
diet. In addition to altering dietary intake, the amount of fat 
entering the body can be reduced by targeting the enzymes 
involved in lipid digestion and absorption pathways.32 Such 
an approach would have the advantage of reducing energy 
entering the body without targeting the central nervous sys-
tem, avoiding the side effect issues that have dogged many 
appetite-suppressing agents.41
The inhibition of fat digestion and absorption is not 
without side effect issues. As detailed later, GI distress Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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and   vitamin deficiencies remain a concern with current 
  treatments. However, humans can tolerate a certain degree of 
inhibition of fat absorption, sufficient to prevent a significant 
amount of energy entering the body. Given that fat contains 
9 kcal/g, the inhibition of the absorption of 30 g/day would 
produce a daily deficit of nearly 300 kcal.42 This, in addition to 
a mildly hypocaloric, well-balanced diet, could theoretically 
produce weight loss of 0.5 kg/week. Once the excess weight 
is lost, the therapy could be modified for long-term weight 
maintenance. For the treatment of hyperlipidemia alone, 
perhaps even less limited inhibition of fat absorption could 
produce desirable results. Moreover, the benefits of reduc-
ing fat absorption are not restricted to weight loss. Specific 
reduction of lipid levels in subjects with hyperlipidemias 
would lead to health benefits beyond those expected through 
reduction in caloric intake and weight loss alone.
HPL isolated C-terminal domain
The fact that HPL activates when it forms a complex between 
its C-terminal region and colipase has brought attention to 
a relatively new strategy to reduce the activity of HPL.43 
The isolated C-terminal domain has shown potential HPL 
inhibitory activity, both in vitro44 and in rodents45 it behaves 
as a colipase lure. Studies in humans are required to test the 
effectiveness of this strategy.
Cetilistat
Cetilistat (ATL-962, Alizyme®; Takeda Pharmaceutical) was 
developed with the aim of creating a drug similar to orlistat 
(see below) but without its side effects. Although cetilistat 
has shown inhibitory activity for both rat and HPL (IC50 of 
54.8 nmol/L and 5.95 nmol/L respectively) it can be seen from 
the IC50 that this component is a much more efficient inhibi-
tor of HPL than rat lipase. Administration of cetilistat (3 to 
100 mg/kg) to diet-induced obesity (DIO) rats exposed to oral 
fat loading reduced plasmatic TG elevation with a correspon-
dent increase in fat excretion in a dose dependent manner. This 
reduced body weight gain and white adipose tissue weight.46 
A phase I study showed that cetilistat increases fecal fat 
excretion in a similar way to orlistat but with a better reported 
tolerability.47 Phase IIb studies showed that its administration 
(180 to 720 mg/day) to obese individuals with and without 
type II diabetes on a hypocaloric moderate fat diet produced 
significant weight loss when compared to subjects receiving 
placebo.48,49 The reported adverse effects were similar to those 
in the placebo group. Despite its reported efficacy and reduced 
adverse event profile, further   development of cetilistat for 
obesity treatment has been discontinued by Takeda.
Lipase inhibitors from plants
In the continuing search for novel anti-obesity agents, numer-
ous plant derived phytochemicals have been screened for 
potential lipase inhibition activity. A recent extensive study 
examined 132 extracts from 106 plant species, used either as 
foods or medicinal herbs, screening them for pancreatic lipase 
inhibition activity.50 Surprisingly, the majority of extracts, 
100 in total, exhibited some degree of inhibitory activity. All 
extracts from plants belonging to Brassicaceae, Ericaceae, 
Fabaceae, Rosaceae and Solanaceae showed inhibitory activ-
ity. Twenty-six extracts inhibited lipase activity by at least 
40%, of which 10 exhibited over 70% inhibitory activity. 
All extracts from apples exhibited more than 70% inhibi-
tory activity. The current review classifies these botanically 
derived inhibitors into the following chemical classes.
Saponins
Saponins are phytochemicals which can be found in the roots 
and rhizomes of most vegetables, beans and herbs. Saponins 
are glycosides known for their soap-like foaming ability 
when mixed with water. This foaming ability results from 
the combination of a lipophylic sapogenin and a hydrophilic 
sugar part.51 Certain saponins such as oleanane, lupine and 
dammarane-type can inhibit pancreatic lipase activity and 
therefore have potential as treatments that could prove 
effective for obesity and related disorders.52–54 However, the 
clinical potential of saponins remains difficult to judge with 
such limited clinical data available.
Acanthopanax senticosus (Rupr. Maxim) Harms
A. senticosus, also known as Siberian Ginseng or Eleuthero-
coccus senticosus, is a shrub commonly found in the northeast 
of Asia. Crude A. senticosus extracts have been used to treat 
physiological changes induced by stress,55,56 some allergic 
and inflammatory conditions,57,58 cancer,59 chronic bronchitis, 
hypertension, ischemic heart disease, and gastric ulcers.60 
So far, 26 triterpenoid saponins have been isolated from the 
leaves and fruits of A. senticosus52 among which ciwujiano-
side C1, tauroside H1, 3-O- α-L-rhamnopyranosyl-( 1→2)- 
α-L-arabinopyranosyl mesembryanthemoidigenic acid, 
acanthopanaxoside C, acanthopanaxoside E, silphioside F, 
copteroside B, hederagenin 3-O- β-D glucuronopyranoside 
6’-O-methyl ester and gypsogenin 3-O- β-D-glucuronide, 
sessiloside and chiisanoside exhibit pancreatic lipase inhibi-
tory activity in vitro with IC50 values ranging from 0.22 to 
0.29 mM.52,61 Studies performed in vivo have shown that 
in DIO rats62 and C57BL/6J mice, administration of an 
A. senticosus extract (12 mg/kg for 12 weeks) decreased Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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the deposition of abdominal fat and improved associated 
lipid parameters, such as increasing serum high-density 
lipoprotein (HDL) cholesterol, and decreasing serum TG, 
low-density lipoprotein (LDL) cholesterol, and hepatic TG.63 
In a placebo controlled study, administration of concentrated 
extracts of A. senticosus (1500 mg/day for 6 months) to 
postmenopausal women decreased serum LDL levels and 
LDL/HDL ratios without associated side effects.64 However, 
since A. senticosus extracts have several mechanisms of 
action including the inhibition of hepatic lipogenic enzymes 
and glucose 6-phosphatase,65 the reduction of LDL levels is 
probably the result of a combination of effects. The effects 
of A. senticosus extract on body mass and body composition 
remain to be demonstrated.
Acanthopanax sessiliflorus sessiloside  
and chiisanoside
These are lupine-type saponins found in the leaves of 
A. sessiliflorus. In vitro studies have shown that both 
sessiloside and chiisanoside inhibit HPL activity in a dose-
dependent manner, with IC50 values of 0.36 and 0.75 mg/mL, 
respectively.53 In mice, simultaneous administration of oil and 
chiisanoside (100 and 300 mg/kg) decreased plasma TG levels 
and increased the amount of undigested TG in the intestinal 
lumen.66 No clinical data are available on A. sessiliflorus.
Aesculus turbinata escins
A. turbinata (Japanese horse chestnut) is a medicinal plant 
widely distributed in north western China. Its dried ripe 
seeds have been employed as a carminative, stomachic, and 
analgesic for the treatment of distension and pain in the chest 
and abdomen.67 The saponins extracted from the seeds are 
called escins. Recently, escins have been reported to show 
inhibition of pancreatic lipase activity (IC50 of 24 mg/mL).68,69 
Administration of escins (0.1% to 0.5% of diet) to mice fed 
a high fat diet prevented body weight gain without altering 
caloric intake. An increase in the levels of undigested fat in 
the mice feces confirmed effective inhibition of fat digestion 
in vivo.70 However, to date there are no published clinical 
data on these effects in humans.
Chinese tea plant saponins
Studies performed with crude saponins extracted from the 
flower buds of the Chinese tea plant Camellia sinensis have 
shown that in mice they accelerate GI transit and also exert 
an inhibitory effect on pancreatic lipase with an IC50 of 
0.091 mg/mL. The main components responsible for these 
effects are the chakasaponins I, II, and III which inhibit 
pancreatic lipase with IC50 values of 0.17 to 0.53 mM. Such 
compounds could be valuable in the prevention of obesity, 
but studies assessing their effect in HPL are needed to assess 
their potential.71
Dioscorea nipponica
D. nipponica Makino is a herb that grows in the   mountainous 
areas of the Korean peninsula. It has long been used as a 
popular remedy for the treatment of several diseases includ-
ing asthma, rheumatoid arthritis and bronchitis.72 The extract 
of D. nipponica appears to inhibit porcine pancreatic lipase 
activity with IC50 values of 5 to 10 mg/mL. Dioscin and 
its aglycone diosgenin are the result of further purification 
  processes. When administered to mice, both   components have 
been shown to suppress increases of blood TG   following oral 
administration of corn oil.72 Rats fed a high fat diet contain-
ing 5% of D. nipponica had significantly lower body weight 
gain that their control counterparts. This was accompanied 
by decreases in blood TG, very-low-density lipoproteins 
(VLDL) and LDL.72 The effects of D. nipponica on body 
weight have yet to be proven in a clinical study.
Oolong tea saponins
Three types of tea, green, oolong and black are used all over 
the world as traditional healthy drinks. Green and oolong tea 
have been reported to exert anti-obesity and hypolipidemic 
actions. Black tea also contains many active ingredients;73 
however some may not survive processing. These teas contain 
several different active ingredients that may exert anti-obesity 
actions through various mechanisms. Oolong tea contains two 
saponins (theasaponins E1 and E2) that seem to competitively 
inhibit pancreatic lipase activity with Km and Vmax values 
of 1.42 mg/mL and 476.2 nkat/L respectively. The Ki value 
of tea saponin is 0.25 mg/mL.73,74 However, to date no studies 
of in vivo activity of these saponins have been reported.
Panax japonicus chikusetsusaponins
The rhizomes of P . japonicus C.A. Meyer (Japanese name; 
Chikusetsuninjin), have been used as a folk medicine 
for hypertension, arteriosclerosis and diabetes.75 In vitro 
total chikusetsusaponins as well as chikusetsusaponin III, 
28-deglucosyl-chikusetsusaponin IV and 28-deglucosyl-
chikusetsusaponin vs inhibit pancreatic lipase activity at 
concentrations of 125 to 500 μg/mL.76 One study showed that 
the administration of total chikusetsusaponins (1% to 3% in 
diet) significantly suppressed weight gain in DIO mice.76 This 
effect was independent of energy intake and correlated with 
a significant reduction in parametrial adipose tissue weight. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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In addition, a reduction of plasma TG levels was observed.76 
Clinical studies on the effects of chikusetsusaponins on body 
composition or body mass have yet to be published.
Platycodin saponins
Platycodin saponins are the main constituents of Platycodi 
radix. Platycodi radix is the root of Platycodon grandiflorum 
A. DC (Campanulaceae), commonly known as Doraji.77 
Some Asian cultures use Platycodi radix in cooking and 
also as a traditional oriental medicine ingredient. Some 
evidence shows that Platycodi radix extracts possess some 
health benefits such as the improvement of hypercholester-
olemia and hyperlipidemia.78 The saponin-rich fraction of 
Platycodi radix has an inhibitory effect on HPL and this 
seems to correlate with anti-obesity actions.79–82 Among the 
various saponins, platycodin D possesses the strongest HPL 
inhibitory activity with a Ki of 0.18 mM.82 Nevertheless, a 
study by Zhao et al83 found that in rats, the decrease in body 
weight correlated with decrease in caloric intake, an effect 
not obviously attributable to lipase inhibition. They ascribed 
this effect to the ability of Platycodin saponins to reduce 
gastric secretion,84 which in turn would slow gastric diges-
tion, decreasing subsequent food intake. These results, taken 
together, suggest that Platycodin saponins provide a potential 
alternative treatment for both obesity and hyperlipidemia.80,81 
However, further data showing replication of these effects 
in humans are needed.
Sapindus rarak DC
S. rarak is a tree found in South and Southeast Asian coun-
tries. The pericarps have anti-pruritic actions.85 A recent 
in vitro study has shown that the methanolic extract from 
S. rarak pericarps exerts pancreatic lipase inhibitory activity 
(IC50 = 614 μg/mL). This extract contains several saponins 
of which rarasaponins I and II and raraoside A inhibited 
pancreatic lipase with IC50 of 131 μM, 172 μM and 151 μM 
respectively.86 The in vivo effects of S. rarak saponins 
remains yet to be investigated.
Scabiosaponins
Scabiosa tschiliensis Grun. (Dipsacaceae) is a perennial herb 
widely distributed in Mongolia and China. S. tschiliensis 
flowers are traditionally used as a remedy for headache, 
fever, cough, and jaundice.87 In vitro studies have reported 
that scabiosaponins E, F, G and I, hookeroside A and B, and 
prosapogenin 1b inhibit HPL. Of these, prosapogenin 1b 
reportedly possesses the greater inhibitory activity at a 
concentration of 0.12 mg/mL. This dose produced lipase 
inhibitory activity comparable to 0.005 mg/mL of orlistat 
in the same model.87 The fact that to date no studies in vivo 
have been reported could be due to the difficulties in   isolating 
these compounds. However, recently scabiosaponins E, F, 
and G have been successfully synthesized.88
Polyphenols
Polyphenols are chemical compounds characterized by the 
presence of more than one phenol unit or building block per 
molecule. Fruit skins contain high levels of polyphenols. The 
health benefits of specific polyphenols are well-documented. 
Polyphenols possess antioxidant actions and are also able to 
inhibit digestive enzymes, these two actions could lower the 
risk of cardiovascular disease and cancer.89 Naturally occur-
ring polyphenols, and in particular catechins and condensed 
tannins isolated from various plant sources, have been shown 
to inhibit digestive enzymes including lipase and α-amylase 
in vitro 90–92 and therefore have some potential in the manage-
ment of obesity.
Apple polyphenols
Apples contain several phenolic substances (ie, chlorogenic 
acid, (+)-catechin, epicatechin, phloridzin, rutin, and pro-
cyanidins (condensed tannins).93 Procyanidins in apples are 
mainly composed of various polymerized catechins. Apples 
and their polyphenol (AP) extract have several biological 
activities such as antioxidant,94 anti-allergy95 and anti-tumor 
activity.96 In a recent study performed by Sugiyama et al97 
it was found that AP inhibited pancreatic lipase activity in 
a dose-dependent manner with an IC50 value of 5.6 μg/mL. 
In addition, the procyanidin fractions extracted from AP also 
inhibited pancreatic lipase activity in a dose-dependent man-
ner with an IC50 value of 1.4 μg/mL. In mice, AP administra-
tion (200 mg/kg) significantly decreased plasma TG after corn 
oil loading. The procyanidin fraction also tended to inhibit TG 
absorption as compared with the control group. Administra-
tion of AP (600 mg) containing capsules to humans inhibited 
TG elevation after TG load when compared to subjects receiv-
ing placebo. No side effects were reported.97
Cassia mimosoides L. var nomame Makino  
(Nomame Herba)
C. mimisoides is a leguminous plant grown in Japan and 
China. Its ethanol extract, CT-II, possesses a dose dependent 
inhibitory action on porcine lipase.98 When administered 
to rats fed high fat diets, CT-II (1% to 3.5% of diet) dose 
dependently suppressed body weight gain, and lowered 
parametrial fat and liver weight when compared to control 
animals.98 The effects of CT-II on body weight in humans 
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Grape seed extracts
Grape seeds and skins contain a variety of health-promoting 
polyphenols, also known as condensed tannins or proantho-
cyanidins.99 Currently these polyphenols are the focus of 
research to elucidate their putative beneficial effects.100 Grape 
seed extract at a concentration of 1 mg/mL inhibits 80% of 
lipase activity.101 Importantly, in vivo these extracts seem 
to lack toxicity. Further studies in animal models are needed 
to evaluate it potential as a weight loss product.102
Terpenes
Terpenes are a large class of hydrocarbons, produced by a 
broad variety of plants. Chemical modification of terpenes 
yields terpenoids. Both terpenes and terpenoids are the 
main constituents of the essential oils of many plants. These 
include carnosic acid, carnosol, crocin and crocetin.
Carnosic acid and carnosol
Carnosic acid and carnosol are compounds extracted from the 
leaves of Salvia officinalis L. (sage). Both substances exert 
inhibitory activity on pancreatic lipase with IC50 values of 
36 and 13 μM, respectively. Although carnosol possesses the 
stronger inhibitory activity in vitro, in vivo it seems to lack 
substantial effects. This has been attributed to its instabil-
ity in suitable solvents.103 Administration of carnosic acid 
(20 mg/kg/day, by mouth) to mice fed a high fat diet, it 
reduced body weight gain and the accumulation of epididy-
mal fat.104 To date studies in humans are lacking.
Crocin and crocetin
Gardeniae fructus is used as a Chinese traditional medicine 
mainly for its analgesic and antipyretic effects. It contains 
geniposide and crocin as main components.105 These com-
ponents exhibit antioxidant, antitumoral and neuroprotec-
tive effects.106–108 In vitro, crocin and its metabolite crocetin 
potently inhibit pancreatic lipase. The most potent inhibitor 
was crocetin, with an IC50 value of 2.1 mg/mL.109 In mice 
fed a high fat diet, crocetin and crocin inhibited the incre-
mental increase in body weight compared with that of the 
control group. These compounds also significantly reduced 
epididymal fat pad mass. Their potency at a dose of 50 mg/kg 
is comparable with that of orlistat at a dose of 10 mg/kg.109 
Crocin and crocetin have yet to be tested in a clinical trial.
Lipase inhibitors derived from 
microbial sources
Lipstatin
Lipstatin, a compound isolated from Streptomyces toxytri-
cini, is a very potent and selective irreversible inhibitor of 
pancreatic lipase. The IC50 of lipstatin for pancreatic lipase is 
0.14 μM.110 Tetrahydrolipstatin or orlistat (THL, Ro 18-0647, 
Xenical®; Hoffmann-La Roche, Basel, Switzerland) is a 
highly lipophilic hydrogenated derivative of lipstatin.111,112 
Orlistat is a potent inhibitor of most mammalian lipases. 
Therapeutic doses of orlistat generally achieve around 35% 
inhibition of lipid digestion.111,113,114 Thus as a consequence 
the undigested fat is not absorbed but excreted.115 Beyond 
its lipase inhibition activity, orlistat reportedly does not sig-
nificantly diminish the activity of other intestinal enzymes. 
Less than 1% of orlistat itself is absorbed, preventing inhi-
bition of extra intestinal lipases.116 When administered by 
intraduodenal infusion in a rat model it almost completely 
inhibited the absorption of cholesterol.117 In humans, initial 
studies showed that orlistat administration at doses between 
375 and 750 mg/day decreased fat absorption and therefore 
increased fat elimination which caused side effects related 
to the amount of fat in the diet. In both rodent and human 
participants short-term orlistat administration increases 
fecal fat loss which returns to baseline after cessation of 
dosing.116,118,119 This product has been evaluated in many 
clinical studies for obesity treatment. After 1 year   treatment, 
the combination of orlistat (120 mg taken three times daily 
just before feeding) and a hypocaloric diet produced a 
higher weight loss compared with placebo.120,121 Although 
the weight reduction from baseline was no greater than 10% 
(4% placebo subtracted),120,121 orlistat significantly decreased 
glycemia, glycated hemoglobin, insulin resistance and car-
diovascular disease risk factors such as hyperlipidemia and 
high blood pressure.122,123 It is not yet known how quickly 
weight is regained on cessation of treatment, however in 
trials in which patients were re-randomized to placebo after 
one year of treatment they regained some but not all of the 
weight lost from baseline.124 In the UK, Clinical Excellence 
guidelines currently recommend that orlistat should not be 
continuously used for more than 24 months.125 Such precau-
tions are advisable because of the limited data available on 
the effect of orlistat administration for longer than two years 
(only the XENDOS study administered the drug continuously 
for 48 months) and side effect issues. Specifically, orlistat 
has shown to slightly impair the absorption of liposoluble 
vitamins A, E, and β-carotene,116,126 however, vitamin supple-
mentation is only required in a minority of patients. Orlistat 
accelerates gastric emptying, this could lead to exaggerated 
postprandial hyperglycemia,127 and the presence of undi-
gested fat in the bowels causes side effects (such as diarrhea, 
abdominal pain, oily stools and fecal spotting) that limit use 
of orlistat.128 Additionally, chronic GI ailments like irritable 
bowel syndrome are clear contraindications for its use. These Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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issues, along with the potential for abuse of this drug as a 
purgative, have caused some concern. Nonetheless, a half 
dose of orlistat (Alli®, 60 mg rather than 120 mg 3 times 
daily) has been approved in Australasia, USA and the EU for 
over-the-counter use.128 Data from very recent studies report 
that the administration of half dose of orlistat in conjunction 
with a reduced calorie, lower-fat diet to overweight and 
obese participants significantly reduced their body weight 
(5.96 kg vs 3.91 kg) waist circumference and visceral fat 
(15.7% vs 9.4%).129,130 It is important to note that both studies 
this dose was well tolerated by participants. To summarize, 
orlistat in conjunction with behavioral modifications could 
become useful therapies for the treatment of obesity and/or 
hyperlipidemia.118
Panclicins
Panciclins A, B, C, D, and E are pancreatic lipase inhibi-
tors isolated from Streptomyces sp. NR 0619. Structurally, 
panclicins A, B, C, D, and E are analogs (but not irreversible 
inhibitors) of tetrahydrolipstatin, which contains a β-lactone 
and an N-formyl leucine ester. The IC50 of panclicins A, B, 
C, D, and E for porcine pancreatic lipase are 2.9, 2.6, 0.62, 
0.66, and 0.89 μM, respectively.131 To date, no studies in 
animal models have been performed.
ebelactones
Ebelactone B, which is obtained from Streptomyces aburavi-
ensis, produces potent inhibition of pancreatic lipase. When 
administered (10 mg/kg, 60 min prior to feeding) to rats 
fed a high fat diet, it inhibited fat intestinal absorption in a 
dose-dependent manner. It also decreased plasmatic levels 
of TG and cholesterol. No data on animal weight or adipos-
ity are reported.132
vibralactone
Vibralactone is a compound isolated from the culture broth 
of the polypore Boreostereum vibrans. In vitro it inhibits 
pancreatic lipase with an IC50 of 0.4 μg/mL.133 Studies in 
animal models are required to test vibralactone’s effective-
ness and possible undesirable effects.
Drugs that interfere  
with carbohydrate absorption
Inhibition of α-amylase and brush border disaccharidases 
would lead to decreased absorption of all the main car-
bohydrates in the diet (glucose absorption would not be 
affected). This in theory would have several benefits, as 
blocking these enzymes would decrease the absorption of 
calories thereby promoting weight loss. These compounds 
have pharmacological potential for helping with weight loss 
and then maintaining weight without a dramatic reduction in 
carbohydrate intake. In addition, since carbohydrate absorp-
tion is affected, these products would reduce the magnitude of 
postprandial glucose and insulin responses to dietary carbo-
hydrates. The modulation of this response could prove to be 
clinically useful in the management of diabetic individuals. 
α-amylase inhibition delays gastric emptying by increasing 
the amount of undigested carbohydrate in the ileum.134,135 
Therefore, amongst other effects, amylase inhibition could 
modulate GI function and gut peptide release, strengthening 
satiety and decreasing food intake by mechanisms including 
reduced gastric emptying.
Acarbose
Acarbose (Bay g 5421, Glucobay®, Precose®, Prandase®; 
Bayer) is a pseudotetrasaccharide that inhibits intestinal 
α-glucosidase reversibly at the brush border of intestinal 
mucosa. As a consequence, the transformation of disaccha-
rides to monosaccharides is prevented, the uptake of monosac-
charides is retarded and thus postprandial insulin and glucose 
levels are reduced.136,137 A study by Samulitis et al138 showed 
that in vitro, acarbose (4 μM) strongly inhibited the activities 
of α-amylase and sucrase (98 and 63%, respectively). At a 
higher concentration (200 μM) it also inhibited isomaltase 
activity (28%) with negligible effects on trehalase and lactase 
activities. Reported adverse reactions are rare with this drug. 
Gradual dose increments prevent GI side effects. Studies 
in rats have reported a dose-dependent reduction of weight 
gain.139 The administration of acarbose to weight-reduced 
women limited weight regain.140 In a one year, double-blind, 
randomized, placebo-controlled study in type 2 diabetes sub-
jects, the individuals receiving acarbose lost 0.5 kg while the 
placebo group gained 0.3 kg.141 Administration of acarbose 
(150 mg/day) to women with polycystic ovary syndrome 
significantly reduced body weight and BMI.142–144
Deoxynojirimycin (DNJ)
DNJ is a polyhydroxylated alkaloid isolated from mulberry 
trees which act as a competitive inhibitor of small-intestinal 
brush-border α-glucosidase.145 Recent reports have consid-
ered sericulture products containing DNJ to be suitable for 
use as functional foods and food additives. In diabetic rats, 
the administration of DNJ (20 mg/kg) prevents weight gain.146 
Synthetic derivatives of DNJ have been developed; they 
include competitive inhibitors BAY o 1248 (emiglitate) and 
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Dovepress 
Dovepress
135
Digestive enzyme inhibition in the management of obesity
potent α-glucosidase inhibitors. At doses ranging from 0.1 to 
5 μg/mL, they inhibit sucrase (up to 97%) and glucoamylase 
(up to 96%). BAY m 1099 also reduced lactase activity (up to 
56%). Interestingly, none of these compounds seem to inhibit 
α-amylase. In contrast to acarbose, the DNJ derivatives at 
high concentrations (20 to 200 μM) considerably inhibited 
trehalase and lactase (a β-galactosidase) activities.138 When 
administered to diabetic rats, BAY o 1248 inhibited weight 
gain in animals fed a diet high in starch while it did not have 
any effect on animals fed with glucose.147 In support of find-
ings obtained from animal experiments, BAY o 1248 (10 mg) 
and BAY m 1099 (50 mg) delayed sucrose absorption and 
prevented post prandial increases in glucose in healthy 
male volunteers.148 However, 60% of participants reported 
intestinal side effects such as flatulence and diarrhea,149 an 
undesirable effect due to increased amounts of fermentable 
(undigested) carbohydrates.
extracts of black, green,  
and mulberry teas
In vitro studies suggest that extracts of black, green, and mul-
berry teas could interfere with carbohydrate and TG absorption 
due to their ability to inhibit α-amylase,150 α-glucosidase,151 
sodium-glucose transporters,152 and pancreatic lipase.153 
Administration of a combination of green (0.1 g), black (0.1 g), 
and mulberry (1.0 g) tea leaves which contained approximately 
5 mg DNJ-type compounds, 100 mg epicatechin gallate, 
300 mg epigallocatechin gallate, and 100 mg theaflavin to 
humans reduced carbohydrate (derived from starch) absorption 
by 25%.153 To date, no in vivo studies have been carried out.
Phaseolus vulgaris L.
The purified, non-toxic (P . vulgaris contains toxic   substances) 
extract of P . vulgaris (kidney bean) contains large amounts 
of phaseolamine (Phase 2®; previously sold as Phaseolamin 
2250®, referring to 1 g of the product blocking 2250 starch 
calories, DEcarb®), a glycoprotein that inhibits α-amylase in 
a non competitive manner.154,155 In the US, several different 
preparations are commercially available for the treatment of 
obesity. In vitro studies have demonstrated that phaseolamine 
binds to α-amylase forming a 1:1 complex inhibiting the 
enzyme. In rats intragastric phaseolamine administration 
reduces post-prandial as well as basal plasma glucose 
levels.156–158 In addition, phaseolamine reduces food intake 
and consequently body weight.139,157,159,160 Apart from the 
inhibition of α-amylase, P . vulgaris extract seems to stimu-
late CCK release, and interfere with central mechanisms that 
regulate food intake and food palatability.161 Administration 
of large doses of phaseolamine impairs the growth rate of 
rats.162 Studies performed in humans have shown contradic-
tory results. For instance, three studies have failed to show 
any measurable inhibition of starch hydrolysis or significant 
weight loss in vivo,155,163–165 suggesting either the existence of 
an alternate route capable of degrading starch or insufficient 
amounts of inhibitors reaching the substrate. Subsequent 
studies showed that intraduodenal administration of the 
partially purified inhibitor significantly inhibited α-amylase 
activity during the ingestion of a starch diet.166 Additional 
studies in normoglycemic and diabetic individuals found that 
phaseolamine administration produced an earlier reduction 
of postprandial glucose levels than controls, with 57% lower 
glucose absorption.167,168 Acute administration of 1.5 g of 
phaseolamine to healthy participants blocked the absorp-
tion of 66% of carbohydrates present in a standard meal.169 
A 30-day, double-blind, placebo-controlled clinical trial for 
weight loss that compared Phase 2 versus placebo reported a 
4% loss of body weight compared with 0.47% in the placebo 
group. This was accompanied by a 10% reduction in body 
fat in the experimental group.170 In 2007, Celleno et al171 and 
Udani and Singh172 conducted randomized, double-blinded, 
placebo-controlled studies on normal and overweight male 
and female volunteers during which some participants were 
prescribed a high carbohydrate diet. After 1 month of chronic 
administration (445 to 1000 mg/day) participants receiving 
P . vulgaris extract showed a significant reduction in both total 
body mass and BMI compared to control, accompanied by 
changes in body composition. This was shown by significant 
reductions in total fat mass, fat deposition, and waist/hip/
thigh circumferences while maintaining lean body mass. 
At the moment, the long-term consequences of intraluminal 
amylase inhibition are not known. Therefore longer studies 
with a larger pool of subjects are required to investigate these 
effects and validate the above-mentioned findings.
Both anti-lipase and anti-amylase 
activity
Berry polyphenols
Berry polyphenols, such as anthocyanins and ellagitannins 
have been shown to reduce postprandial hyperglycemia.173 
Although in vitro anthocyanins can directly induce secre-
tion of insulin from pancreatic cells,174 their main effect on 
postprandial hyperglycemia seems mainly due to inhibition 
of α-glucosidase and α-amylase.175 In addition, in vitro this 
extract also exerts inhibitory activity on pancreatic lipase. 
Ellagitannin-rich extracts such as (raspberry, strawberry, 
cloudberry and arctic bramble) seem to be the most   effective Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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at inhibiting lipase.176 Some published data suggest that 
extract-induced fecal lipid excretion is associated with reduc-
tions in weight gain and changes in TG metabolism,97,177 while 
other studies report no significant correlations.178 The lack of 
effects found in some studies could be due to compensatory 
increases in lipase secretion similar to those seen in studies 
on condensed tannins in rats.90 The demonstration of lipase 
inhibition in vivo by berry components needs to be fully 
demonstrated before there can be any serious investigation 
of their weight management potential.
Cyclocarya paliurus (Batal.) iljinskaja
C. paliurus is a tree found in the highlands of southern China. 
It is used as a folk remedy for several ailments. Cyclocari-
oside A, II and III are triterpenoid saponins isolated from the 
leaves of C. paliurus. It is known that triterpenoid saponins 
exhibit an insulin-like activity in adipocytes, in vivo and 
in vitro.179 Therefore, this could be one mechanism respon-
sible for the beneficial effects of these compounds. In vitro, 
C. paliurus extract showed inhibitory activity toward pancre-
atic lipase, with an IC50 of 9.1 μg/mL.180 Administration of 
C. paliurus extract (250 mg/kg) to mice after a load of dietary 
fat suppressed the expected increase in plasma triacylgyc-
erol levels.180 Taken together these results suggest that the 
hypolipemic action of C. paliurus extract is probably due to 
lipase inhibition. In vitro studies have shown α-glucosidase 
inhibitory activity at the dose of 5 μg/mL. Administration 
of a C. paliurus extract (250 mg/kg) to mice suppressed the 
expected increase of blood glucose level following sucrose 
administration.181 In addition, the oscillations in blood glu-
cose levels found in genetically hyperglycemic obese KK-AY 
mice were significantly lower when C.   paliurus (2 g/day) 
extract was administered daily for 3 weeks. To date, no 
research has been conducted on the hypoglycemic effect of 
this extract in clinical settings
Green tea
In Asia, green tea is widely consumed and for centuries 
has been thought to exert significant health promoting 
effects.182 The long-term consumption of green tea and its 
extract (GTE) (commercially available as pills, patches, 
gums, mints, extracts, and ice creams) has been associated 
with weight loss mainly through a thermogenic mecha-
nism.183 Compared to other teas, green tea catechins have 
been the most extensively investigated. Because green 
tea is derived from an oxidation-free process, high levels 
of catechins are retained. In contrast, the full fermenta-
tion processes used to produce black tea significantly 
reduce catechins levels.184 The main active ingredients 
in GTE: the catechins epigallocatechin gallate (EGCG; 
Teavigo®), epigallocatechin (EGC), epicatechin gallate 
(ECG), and epicatechin (EC) are responsible for many of 
the beneficial effects of green tea.185,186 In vitro data sug-
gest that the anti-obesity effects of green tea could in part 
be mediated through the inhibition of adipocyte division 
and maturation.187–189 There is also evidence that green tea 
could reduce glucose and fat absorption by inhibiting GI 
enzymes involved in nutrient digestion.190,191 Juhel et al192 
reported that in vitro the green tea extract AR25 (Exolise®; 
standardized at 25% catechins) effectively inhibited gastric 
and pancreatic lipase activities. In addition, tea polyphenols 
have been shown to inhibit α-amylase and α-glucosidase 
in vitro.191 It has been shown that green tea catechins 
reduced α-amylase and sucrase activities in rat intestine.191 
A study performed in streptozotocin-induced diabetic rats 
showed that addition of green tea extracts to the diet (0.01% 
and 0.2% of diet) significantly reduced maltase (both doses) 
as well as saccharase and lactase (higher dose) activities.193 
Administration of green tea extract (3% of diet) to rats fed 
a high fat diet decreased body weight gain and visceral 
fat accumulation, this correlated with an increase in fecal 
lipids.194 An open study carried out in moderately obese 
patients showed that administration of AR25 for 3 months 
decreased body weight and waist circumference by 4.6% 
and 4.48% respectively.195 Again, these effects could be 
the result of the aforementioned combination of enzyme 
inhibition and increased thermogenesis.
Nelumbo nucifera extract (NNe)
N. nucifera Gaertn. is a large aquatic herb widely found in 
India and China. Its extracts seem to have anti-inflammatory,196 
antipyretic197 and antioxidant properties.198 In vitro studies 
have shown that NNE inhibits lipase and α-amylase activ-
ity with an IC50 value of 0.46 mg/mL and 0.82 mg/mL 
respectively. This effect was dependent upon the phenolic 
compounds present in the extract since its elimination abol-
ished NNE inhibitory activity.199 In DIO female mice, treat-
ment with NNE (5% of diet) and exercise decreased body 
weight, parametrial adipose tissue weight and liver TG levels, 
this effect was not seen in the exercise only group.199 Oral 
administration of NNE to glucose-fed hyperglycemic and 
streptozotocin-induced diabetic rats markedly reduced blood 
sugar levels when compared with control animals. In normal 
animals, NNE administration improved glucose tolerance 
and potentiated the action of exogenously injected insulin. 
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Oolong tea catechins
Catechins in oolong tea are reported to prevent DIO by inhibit-
ing small intestine micelle formation,201 limiting the absorption 
of sugars by inhibiting α- glucosidase activity.202 Epigallocat-
echin 3-O-gallate (EGCG) is one of the main polyphenols in 
oolong tea. In vitro, it inhibits pancreatic lipase with an IC50 
of 0.349 μM. In addition, flavan-3-ol digallate esters, such as 
(-)-epigallocatechin-3,5-digallate also possess inhibitory lipase 
activity with an IC50 of 0.098 μM.203 In DIO mice, oolong tea 
catechins suppressed increases in body weight, parametrial 
adipose tissue weights, and adipose cell size by delaying the 
absorption of dietary fat from the intestine by inhibiting pan-
creatic lipase activity.73 In a double-blind, placebo-controlled 
study, 12 weeks daily administration of oolong tea (containing 
690 mg of catechins) to normal and overweight males (with 
daily EI set at 90%) produced a significant reduction in body 
weight (1.5%), BMI (1.5%), waist circumference (2.0%), and 
body fat mass (3.7%), compared to the placebo group.204 These 
results suggest that oolong tea catechin consumption might be 
useful as an adjuvant during weight loss programs.
Peanut and peanut shell extract (PSe)
An aqueous extract of peanut cotyledons has shown specific 
inhibitory activity towards pancreatic and human salivary 
α-amylases205 and lipases.206 The peanut shell extract also 
shows inhibitory effects on human lipase, with a dose of 
10 mg/mL inhibiting 92% of activity.207 When administered 
as 1% of a high fat diet, PSE reduced weight gain in normal 
adult rats without altering food consumption.207
Salacia reticulata
S. reticulata is a climber found in Sri Lanka and India. Its 
stems and roots are used for diabetes treatment. In Japan, 
S. reticulata extract is consumed as a food supplement that 
suppresses postprandial hyperglycemia. The main com-
pounds responsible for α-glucosidase inhibition are salaci-
nol208 and kotalanol.209 S. reticulate polyphenol extracts also 
inhibit pancreatic lipase with an IC50 of 264 mg/L, and among 
the constituents isolated from S. reticulata, catechins showed 
potent inhibitory activity.210 Studies performed in Zucker rats 
and high-fat diet rats have shown that the oral administration 
of a S. reticulata extract (125 mg/kg)   suppressed body weight 
gain without affecting food intake.210 To date no human stud-
ies have been carried out.
Salix matsudana
S. matsudana (Chinese willow) (one ingredient of Rev 
Hardcore® and Methyl Ripped®) is a species of willow native 
to north western China. Its leaves have been used in tradi-
tional Chinese medicine for the treatment of several ailments. 
It has recently been reported that the polyphenol extracts of 
S.   matsudana have anti-obesity actions.211,212 These studies 
showed that oral administration of polyphenol fractions to 
DIO mice reduced adiposity and body weight. In vitro analy-
sis revealed that S. matsudana extract inhibited the enzyme 
α-amylase. In addition, the polyphenol fractions also had 
an effect on lipid absorption since its presence completely 
inhibited the intestinal absorption of palmitic acid, a product 
of oil hydrolysis. The effects of S. matsudana are mainly due 
to the inhibition of carbohydrate and lipid absorption, and 
the acceleration of fat mobilization through enhancement of 
NA-induced lipolysis in adipocytes.211 Although S.   matsudana 
extracts have been shown to have anti-obesity actions in vitro 
and in rodents, research in humans, especially on the long 
term effects, is lacking.
Conclusion
Blocking the digestion and absorption of dietary lipids 
and carbohydrates provides a valuable alternative to other 
pharmacological approaches to obesity. With the recent 
withdrawal of sibutramine from the European market, the 
only globally licensed anti-obesity drug remaining is the 
lipase inhibitor orlistat. This lipase inhibitor has also now 
been licensed in many countries for over-the-counter, non-
prescription weight control. Clinical data suggest that lipase 
inhibition produces greater than anticipated reductions in dia-
betes and cardiovascular risk factors than would be expected 
to be produced by its effects on body weight alone. However, 
the effect of blocking lipase action on meal induced satiety 
signals may produce counterproductive effects on appetite. 
The clinical implications of this have yet to be determined.
Studies in obese patients suggest that lipase inhibitors may 
be particularly beneficial for those who can effectively con-
trol their food intake and adhere to diet restriction. However 
for those with more dysregulated eating behavior, appetite-
suppressing pharmacotherapy might be more efficacious. The 
role of lipase inhibition induced GI side effects in clinical 
weight loss remains to be determined. Do those who use lipase 
inhibitors learn to avoid dietary fat? Or do they learn to avoid 
taking the prescription as intended – for example regularly 
missing doses before the consumption of high fat meals? Little 
evidence exists on the effects of lipase inhibition on dietary 
compliance and claims based on this lack substantiation. 
However, if lipase inhibition does   produce beneficial changes 
in behavior through GI-related side effects, the development 
of side effect-free lipase   inhibitors will be pointless.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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For blocking of the inhibition of carbohydrate digestive 
enzymes, the so-called starch blockers have been available 
for many years. To date, none of these agents have made 
a significant contribution to the effective management of 
obesity. Nonetheless, such products appear to produce 
beneficial effects on blood glucose levels and may have 
benefits in obese diabetic populations. Like lipase inhibi-
tors, these agents will not cross the blood–brain barrier and 
produce CNS related side effects as with traditional appetite 
suppressant/anti-obesity medication, or nausea associated 
with newer incretin-based treatments for obesity and diabe-
tes. A major consequence of blocking digestion of carbohy-
drates in the proximal gut, colonic fermentation, can only 
lead to increased microbial production of gas in the bowel. 
The effects of starch blockers on appetite immediately post-
meal might weaken those processes of satiety dependent on 
rapid glucose absorption (during and immediately post-meal). 
However colonic fermentation may increase late post meal 
satiety signals mediated by the release of short-chain FFA 
such as GLP-1 and PYY, and FFA oxidation in the liver. 
Overall, it can be concluded that no single compound can be 
considered to be a proven weight control product. Although 
some of the products reviewed above show potentially prom-
ising effects for weight control, for the majority more data 
are needed to define safety, the optimal dose required, and 
the actual magnitude of effects that can be expected during 
use in practice. Moreover, many of these substances may 
also produce adverse side effects.
For the majority of compounds described here, there are 
tantalizing but still inconsistent or incomplete data relating to 
the mechanism of action and benefits for weight control. In 
the majority of cases effects have been demonstrated in vivo 
or to a lesser extent in animal models. For lipase inhibitors, 
although the majority of plant derivatives exert in vitro 
inhibitory activity, the most promising compounds seem to be 
those derived from bacterial sources such as lipstatin and its 
synthetic derivative orlistat. These compounds have proven 
to reduce body weight in humans without significant side 
effects. In terms of the inhibition of carbohydrate digestive 
enzymes, the products that have so far been used with some 
degree of success in humans for the purpose of weight reduc-
tion are acarbose and phaseolamine, the remaining products 
are still in experimental phases. Finally, some phytochemi-
cals such as green and oolong tea extracts, which inhibit both 
lipid and carbohydrate digestive enzymes, seem to have some 
beneficial effects as weight-controlling products.
Improved understanding and evidence on each of the 
reviewed and other proposed weight control ingredients will 
guide further research, as well as the selection of ingredients 
and product formats that can deliver the most attractive and 
effective benefits to consumers. Ultimately, only randomized, 
double blinded, placebo-controlled clinical trials of enzyme 
inhibitors in humans can demonstrate their true potential. 
For all ingredients purported to be useful in weight control, 
significant placebo-subtracted weight loss needs be demon-
strated at least in the medium term, ie, up to 24 weeks of use. 
Nonetheless, inhibition of the breakdown of carbohydrate and 
fat in the GI tract remains a viable means of reducing energy 
absorption and thus overall energy intake. As such they may 
prove useful agents in weight management.
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